To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Russia’s Pharma Industry Impresses as Economy Continues to Grow
29-06-2012: The Russian pharmaceutical industry will continue to expand due to government initiatives and increased healthcare spending, predicts a new report by healthcare business specialists GlobalData.
The report, "Healthcare, Regulatory and Reimbursement Landscape - Russia", states that Russia’s efforts to boost its pharmaceutical sector have been rewarded with strong and steady growth and the increased implementation of domestically produced treatments.
The country’s pharmaceutical market soared from a 2005 valuation of $6.6 billion to almost three times that in 2010, when it was worth approximately $18.7 billion, climbing at a remarkable Compound Annual Growth Rate (CAGR) of 23%.
Following comprehensive data analysis, GlobalData expects this growth to continue at a less staggering, yet still impressive, CAGR of 9.5% to reach $46.4 billion by the end of 2020.
This surge in value is attributed to the introduction of national programs such as Health in 2006, and PharmMed 2020, which made its debut in 2009. As part of the latter, Russia has significantly increased research and development (R&D) spending in the field of drugs innovation and created opportunities for the development of the healthcare industry. Putin’s government has laid out goals to increase the domestic share of the pharmaceutical market to 50% by 2020, and the share of domestic innovative drugs to 60% by the same year.
However, it is not all plain sailing for the Eastern European giant. A lack of clarity in Russia’s regulatory system and a language barrier means foreign Multinational Corporations (MNCs) often face problems when attempting to register drugs and medical devices.
On average, it takes 24 months to register a new drug in an application process that must be carried out in Russian. This often proves restrictive for MNCs who want to progress without seeking legal advice from local distributors or consultants.
Furthermore, according to a new law that came into effect in 2010, foreign manufacturers must also conduct clinical trials in Russia prior to registration, and the results of international trials will only be accepted if they were conducted with the participation of Russian patients.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5A light switch inside the brain
- 6Researchers divide enzyme to conquer genetic puzzle
- 7New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Frost & Sullivan: Opportunities for electronics manufacturing services in me ...
- Frost & Sullivan commends Merck Serono for its excellence in product differe ...
- Emphasis on X-ray quality spurs adoption of radiography, finds Frost & Sullivan
- Demand for hybrid solutions to spur European interventional radiology and ca ...
- Frost & Sullivan: Combination drugs are the future of the European Hepatitis ...
- Analytik Jena: Opening ceremony of new competence center in Moscow with high-ranking guests
- Evonik joint venture for Biolys production in Russia: Executive Board approves realization
- Russia’s Pharma Industry Impresses as Economy Continues to Grow
- Evonik invests in the feed amino acid L-lysine in Brazil and Russia
- Evolva obtains patent coverage in Russia on EV-077 for use in complications of diabetes